Moleculin Accumulated Other Comprehensive Income Trend from 2010 to 2022
MBRX  Stock  USD 1.80 0.18 11.11% 
Moleculin  Accumulated Other Comprehensive Income 
Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin main balance sheet or income statement drivers, such as Interest Expense of 39.7 K, Operating Expenses of 18.6 M or Research and Development Expense of 11.6 M, as well as many exotic indicators such as Total Assets Per Share of 3.74, Quick Ratio of 18.85 or Net Current Assets as percentage of Total Assets of 88.37. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules. It can also supplement various Moleculin Biotech Technical models . Additionally, see the analysis of Moleculin Biotech Correlation against competitors.
Moleculin Biotech Quarterly Accumulated Other Comprehensive Income  22,000 
Moleculin Accumulated Other Comprehensive Income Breakdown
Showing smoothed Accumulated Other Comprehensive Income of Moleculin Biotech CS with missing and latest data points interpolated. A component of Shareholders Equity representing the accumulated change in equity from transactions and other events and circumstances from nonowner sources; net of tax effect; at period end. Includes foreign currency translation items; certain pension adjustments; unrealized gains and losses on certain investments in debt and equity securities.Moleculin Biotech's Accumulated Other Comprehensive Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moleculin Biotech's overall financial position and show how it may be relating to other accounts over time.
Accumulated Other Comprehensive Income  10 Years Trend 

Accumulated Other Comprehensive Income 
Share
Timeline 
Moleculin Accumulated Other Comprehensive Income Regression Statistics
Arithmetic Mean  38,344  
Geometric Mean  37,623  
Coefficient Of Variation  23.06  
Mean Deviation  5,760  
Median  35,000  
Standard Deviation  8,842  
Sample Variance  78,188,650  
Range  34,000  
RValue  0.50  
Mean Square Error  63,926,251  
RSquared  0.25  
Significance  0.08  
Slope  1,136 
Moleculin Accumulated Other Comprehensive Income History
About Moleculin Biotech Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Moleculin Biotech income statement, its balance sheet, and the statement of cash flows. Moleculin Biotech investors use historical funamental indicators, such as Moleculin Biotech's Accumulated Other Comprehensive Income, to determine how well the company is positioned to perform in the future. Although Moleculin Biotech investors may use each financial statement separately, they are all related. The changes in Moleculin Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Moleculin Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Moleculin Biotech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.
Moleculin Biotech, Inc., a clinicalstage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.
Last Reported  Projected for 2022  
Accumulated Other Comprehensive Income  41 K  46.5 K 
Net Income Per Employee  934.9 K  1 M 
Moleculin Biotech Investors Sentiment
The influence of Moleculin Biotech's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decisionmaking process regarding taking a position in Moleculin. The overall investor sentiment generally increases the direction of a stock movement in a oneyear investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moleculin Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moleculin Biotech's short interest history, or implied volatility extrapolated from Moleculin Biotech options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Additionally, see the analysis of Moleculin Biotech Correlation against competitors. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Moleculin Stock analysis
When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio File ImportQuickly import all of your thirdparty portfolios from your local drive in csv format  Go  
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings  Go  
Portfolio RebalancingAnalyze riskadjusted returns against different time horizons to find assetallocation targets  Go  
Price TransformationUse Price Transformation models to analyze depth of different equity instruments across global markets  Go  
Portfolio AnywhereTrack or share privately all of your investments from the convenience of any device  Go 
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization 46.3 M  Return On Assets 0.19  Return On Equity 0.28 
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.